ResearcherColumbia UniversityActive in the last 2 years
Yukihito Kuroda
Matched on ORCID iD 0000-0002-6920-6731; OpenAlex author ID A5058987205. Sources: OpenAlex.
Their work
- Papers
- 8
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2020: 1 paper · 2021: none · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 2 papers
Papers 8
- Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. Co-author DOI 10.1038/s41416-026-03577-w↗
- Targeting the αvβ5 Integrin Modifies the TGFβ-Rich Tumor Microenvironment of Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-4223↗
- Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. Co-author DOI 10.1155/2024/1529449↗
- Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. Co-author DOI 10.3389/fcell.2024.1327772↗
- Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. Co-author DOI 10.1002/ijc.34362↗
- Tumor-resident regulatory T cells in pancreatic cancer express the αvβ5 integrin as a targetable activation marker Co-author DOI 10.1101/2023.05.24.542137↗
- Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. Co-author DOI 10.1111/cas.15846↗
- Novel Pancreatic Cancer Therapy Targeting Cell Surface Glycans by Liposomes Modified with rBC2LCN Lectin. Co-author DOI 10.1159/000513430↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tatsuya Oda · 6 shared papers, 2020–2026 · strength 1.09
- Paper Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. DOI 10.1038/s41416-026-03577-w↗
- Paper Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN l… DOI 10.1111/cas.15846↗
- Paper Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. DOI 10.1155/2024/1529449↗
- Osamu Shimomura · 6 shared papers, 2020–2026 · strength 1.09
- Paper Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. DOI 10.1038/s41416-026-03577-w↗
- Paper Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN l… DOI 10.1111/cas.15846↗
- Paper Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. DOI 10.1155/2024/1529449↗
- Yoshihiro Miyazaki · 5 shared papers, 2020–2026 · strength 0.89
- Paper Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. DOI 10.1038/s41416-026-03577-w↗
- Paper Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. DOI 10.1155/2024/1529449↗
- Paper Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. DOI 10.3389/fcell.2024.1327772↗
- Yoshimasa Akashi · 4 shared papers, 2023–2026 · strength 0.78
- Paper Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. DOI 10.1038/s41416-026-03577-w↗
- Paper Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. DOI 10.1155/2024/1529449↗
- Paper Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. DOI 10.3389/fcell.2024.1327772↗
- Hiromitsu Nakahashi · 4 shared papers, 2023–2026 · strength 0.78
- Paper Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. DOI 10.1038/s41416-026-03577-w↗
- Paper Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. DOI 10.1155/2024/1529449↗
- Paper Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. DOI 10.3389/fcell.2024.1327772↗
- Hiroaki Tateno · 4 shared papers, 2020–2024 · strength 0.67
- Paper Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN l… DOI 10.1111/cas.15846↗
- Paper Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. DOI 10.1155/2024/1529449↗
- Paper Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. DOI 10.1002/ijc.34362↗
- Tomoaki Furuta · 3 shared papers, 2020–2024 · strength 0.47
- Paper Aberrant Glycosylation in Pancreatic Ductal Adenocarcinoma 3D Organoids Is Mediated by KRAS Mutations. DOI 10.1155/2024/1529449↗
- Paper Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. DOI 10.1002/ijc.34362↗
- Paper Novel Pancreatic Cancer Therapy Targeting Cell Surface Glycans by Liposomes Modified with rBC2LCN Lectin. DOI 10.1159/000513430↗
- Kazuki N. Sugahara · 2 shared papers, 2023–2026 · strength 0.43
- Tatiana Hurtado de Mendoza · 2 shared papers, 2023–2026 · strength 0.43
- Kodai Suzuki · 2 shared papers, 2023–2026 · strength 0.43
- Norio Miyamura · 2 shared papers, 2023–2026 · strength 0.43
- Andrew M. Lowy · 2 shared papers, 2023–2026 · strength 0.43
- Koichiro Kumano · 2 shared papers, 2024–2026 · strength 0.42
- Paper Dual-oxygen pancreatic cancer organoids recapitulate basal-classical heterogeneity validated by spatial transcriptomics. DOI 10.1038/s41416-026-03577-w↗
- Paper Hypoxia at 3D organoid establishment selects essential subclones within heterogenous pancreatic cancer. DOI 10.3389/fcell.2024.1327772↗
- Kentaro Hatano · 1 shared paper, 2023 · strength 0.20
- Takahito Nakajima · 1 shared paper, 2023 · strength 0.16
- Sota Kimura · 1 shared paper, 2020 · strength 0.11
- Tsuyoshi Enomoto · 1 shared paper, 2020 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.